Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2011

View Archived Issues

New carbapenem antibiotics described

Irosustat demonstrates pharmacodynamic proof of concept

New DNA vaccine is efficacious in monkey model of tuberculosis

Gantenerumab reduces amyloid levels in brain

Scientists in U.K. identify microRNA biomarker in COPD

Phase I/II data disclosed on trabedersen in melanoma, pancreatic and colorectal carcinoma

Intellikine advances first-in-human trial of INK-1117

Ironwood Pharmaceuticals prepares new GCS activators

Isis Pharmaceuticals selects second development candidate in GlaxoSmithKline collaboration

Dainippon Sumitomo Pharma discloses novel agents for sepsis

ISCO reports promising preclinical results with hpSC-derived neuronal cells

New deuterated dimethylcurcumin derivatives claimed by Concert Pharmaceuticals

Scientists at Gilead Sciences patent new SYK inhibitors

Novel histamine receptor antagonists presented by Kalypsys

Medicago completes first stage of noninfluenza VLP vaccine collaboration agreement

Michael J. Fox Foundation funds clinical study of Parkinson's disease vaccine

ISTA provides update on development of bromfenac ophthalmic solutions

Topline data reported from Pozen's phase III PA-32540 study

FDA grants pre-IND meeting to Advaxis for ADXS-HER2

DSMB recommends continuing Cyclacel's SEAMLESS trial

Micromet outlines registration strategy for blinatumomab

Kissei Pharmaceutical to pay MediciNova for further development of MN-221

Baxter International starts phase III trial of recombinant von Willebrand factor

FDA committee recommends approval of Zilver PTX paclitaxel-eluting stent

Telik commences phase IIb trial of Telintra

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...